Article PDF
References
Silman A, Shipley M . Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 1997;36:599–601.
Jones SK . Chloroquine, hydroxychloroquine and the eye. Royal College of Physicians Dermatology Committee;discussion document, 1996.
Jones SK . Survey of prescribing and screening practices for antimalarial drugs by UK dermatologists, 1996.
Cox NH, Paterson WD . Ocular toxicity of antimalarials in dermatology: a survey of current practice. Br J Dermatol 1994;131:878–82.
Zuehlke R, et al. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981;20:57–61.
Rynes RI, et al. Ophthalmologic safety of long-term hydroxychloroquine treatment. Arthritis Rheum 1979;22:832–6.
Tobin DR, Krobel B, Rynes RI . Hydroxychloroquine: seven year experience. Arch Ophthalmol 1982;100:81–3.
Mantyjarvi M . Hydroxychloroquine treatment and the eye. Scand J Rheumatol 1985;14:171–4.
Morsman CDG, et al. Screening for hydroxychloroquine retinal toxicity. Is it necessary? Eye 1990;4:572–6.
Arden GB, Kolb H . Antimalarial therapy and early retinal changes in patients with rheumatoid arthritis. BMJ 1966;1:270–3.
Nylander U . Ocular damage in chloroquine therapy. Acta Ophthalmol (Copenh) 1996;44:335–47.
Levy GD, et al. Incidence of hydroxychloroquine retinopathy in 1027 patients in a large multicentre outpatient practice. Arthritis Rheum 1997;40:1482–6.
Mackenzie AH . Dose refinements in long term therapy of rheumatoid arthritis with antimalarials. Am J Med 1983;(Suppl):40–5.
Mavrikakis M, et al. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 1996;55:187–9.
Blyth C, Lane C . Hydroxychloroquine retinopathy: is screening necessary? BMJ 1998;916:710–7.
Block JA . Hydroxychloroquine and retinal safety. Lancet 1998;351:771.
Schofield R . Audit of screening for quinolone toxicity 1975-1994. Northwest Regional Audit Office, 1995.
Scherbel AL, et al. Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinopathy. N Engl J Med 1963;273:360–6.
Grierson DJ . Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56:188–90.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fielder, A., Graham, E., Jones, S. et al. Royal College of Ophthalmologists guidelines: Ocular toxicity and hydroxychloroquine. Eye 12, 907–909 (1998). https://doi.org/10.1038/eye.1998.236
Issue Date:
DOI: https://doi.org/10.1038/eye.1998.236
This article is cited by
-
Two years’ experience of screening for hydroxychloroquine retinopathy
Eye (2021)
-
Macular sensitivity changes for detection of chloroquine toxicity in asymptomatic patient
International Ophthalmology (2010)
-
Abnormalities on the multifocal electroretingram may precede clinical signs of hydroxychloroquine retinotoxicity
Eye (2006)
-
Visual Field and Multifocal Electroretinography and their Correlations in Patients on Hydroxychloroquine Therapy
Documenta Ophthalmologica (2006)
-
Ocular Toxicity Due to Chloroquine and Hydroxychloroquine: Electrophysiological and Visual Function Correlates
Documenta Ophthalmologica (2005)